

CORRECTION OPEN



# Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer

Anita Csizmarik, Nikolett Nagy, Dávid Keresztes, Melinda Váradi, Thilo Bracht, Barbara Sitek, Kathrin Witzke , Martin Pühr , Ilona Tornyi , József Lázár, László Takács, Gero Kramer, Sabina Sevcenco, Agnieszka Maj-Hes, Boris Hadaschik, Péter Nyirády and Tibor Szarvas

© The Author(s) 2025

*Prostate Cancer and Prostatic Diseases*; <https://doi.org/10.1038/s41391-025-01064-6>

Correction to: *Prostate Cancer and Prostatic Diseases* <https://doi.org/10.1038/s41391-023-00713-y>, published online 26 August 2023

In Table 2 of this article, the unit for CTAG1A and KLK2 were incorrect and should have read pg/ml and ng/ml respectively.

The incorrect Table 2

**Table 2.** Univariable analysis in patients who underwent Abi or Doc therapy.

Variables		Abi			Doc		
		Overall survival			Overall survival		
		HR	95% CI	p	HR	95% CI	p
Age	>72 y.	1.577	0.967–2.571	0.068	1.591	0.929–2.723	0.091
ECOG	>1	5.386	2.566–11.351	<b>&lt;0.001</b>	1.418	0.824–2.439	0.208
Visceral mets.	pos.	1.031	0.443–2.399	0.944	1.474	0.660–3.293	0.344
LN mets.	pos.	1.344	0.719–2.514	0.354	0.796	0.442–1.433	0.446
Bone mets.	pos.	2.426	0.971–6.058	0.058	2.091	0.506–8.643	0.308
Primary local treatment	pos.	0.600	0.369–0.974	<b>0.039</b>	0.996	0.557–1.779	0.988
Primary RPE	pos.	0.804	0.499–1.296	0.370	0.902	0.451–1.804	0.770
Primary RT	pos.	0.729	0.390–1.360	0.321	1.028	0.482–2.189	0.944
PSA median	<sup>a</sup>	2.529	1.535–4.168	<b>&lt;0.001</b>	0.866	0.505–1.486	0.601
PSA response	present	1.351	0.584–3.126	0.483	0.954	0.474–1.918	0.895
PSA response	>30%	0.600	0.341–1.056	0.076	0.993	0.976–1.011	0.460
PSA response	>50%	0.628	0.379–1.042	0.072	0.973	0.946–1.000	0.054
PSA response	>90%	0.597	0.349–1.020	0.059	0.983	0.852–1.134	0.811
FSCN1 median	<sup>a</sup>	1.764	1.086–2.866	<b>0.022</b>	0.680	0.394–1.174	0.166
FSCN1 (ROC)	<sup>a</sup>	2.182	1.336–3.564	<b>0.002</b>	0.733	0.427–1.258	0.260
CTAG1A (median)	>2.285 ng/ml	0.977	0.912–1.047	0.509	-	-	-
KLK2 (median)	>4.088 pg/ml	1.549	0.963–2.493	0.071	-	-	-

Significant values are indicated in bold. LN - Lymph node, RPE - radical prostatectomy, RT - radiation therapy.

<sup>a</sup>Abi cohort: median (ng/ml): PSA: 66.45, FSCN1: 9.39 /FSCN1 ROC cut-off: 10.22. Doc cohort: median (ng/ml): PSA: 73.69, FSCN1: 5.84 /FSCN1 ROC cut-off: 5.01.

## The corrected Table 2

**Table 2.** Univariable analysis in patients who underwent Abi or Doc therapy.

Variables		Abi			Doc		
		Overall survival			Overall survival		
		HR	95% CI	p	HR	95% CI	p
Age	>72 y.	1.577	0.967–2.571	0.068	1.591	0.929–2.723	0.091
ECOG	>1	5.386	2.566–11.351	<b>&lt;0.001</b>	1.418	0.824–2.439	0.208
Visceral mets.	pos.	1.031	0.443–2.399	0.944	1.474	0.660–3.293	0.344
LN mets.	pos.	1.344	0.719–2.514	0.354	0.796	0.442–1.433	0.446
Bone mets.	pos.	2.426	0.971–6.058	0.058	2.091	0.506–8.643	0.308
Primary local treatment	pos.	0.600	0.369–0.974	<b>0.039</b>	0.996	0.557–1.779	0.988
Primary RPE	pos.	0.804	0.499–1.296	0.370	0.902	0.451–1.804	0.770
Primary RT	pos.	0.729	0.390–1.360	0.321	1.028	0.482–2.189	0.944
PSA median	<sup>a</sup>	2.529	1.535–4.168	<b>&lt;0.001</b>	0.866	0.505–1.486	0.601
PSA response	present	1.351	0.584–3.126	0.483	0.954	0.474–1.918	0.895
PSA response	>30%	0.600	0.341–1.056	0.076	0.993	0.976–1.011	0.460
PSA response	>50%	0.628	0.379–1.042	0.072	0.973	0.946–1.000	0.054
PSA response	>90%	0.597	0.349–1.020	0.059	0.983	0.852–1.134	0.811
FSCN1 median	<sup>a</sup>	1.764	1.086–2.866	<b>0.022</b>	0.680	0.394–1.174	0.166
FSCN1 (ROC)	<sup>a</sup>	2.182	1.336–3.564	<b>0.002</b>	0.733	0.427–1.258	0.260
CTAG1A (median)	>2.285 pg/ml	0.977	0.912–1.047	0.509	-	-	-
KLK2 (median)	>4.088 ng/ml	1.549	0.963–2.493	0.071	-	-	-

Significant values are indicated in bold. LN - Lymph node, RPE - radical prostatectomy, RT - radiation therapy.

<sup>a</sup>Abi cohort: median (ng/ml): PSA: 66.45, FSCN1: 9.39 /FSCN1 ROC cut-off: 10.22 Doc cohort: median (ng/ml): PSA: 73.69, FSCN1: 5.84 /FSCN1 ROC cut-off: 5.01.

The original article has been corrected.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless

indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025